BeOne Medicines AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	5,282	3,810	2,459	1,416	1,176
Other Revenue	60.97	-	-	-	-
Revenue	5,343	3,810	2,459	1,416	1,176
Revenue Growth (YoY)	40.23%	54.96%	73.65%	20.37%	280.83%
Cost of Revenue	668.54	594.09	379.92	286.48	164.91
Gross Profit	4,674	3,216	2,079	1,129	1,011
Selling, General & Admin	2,081	1,832	1,509	1,279	990.12
Research & Development	2,146	1,953	1,779	1,641	1,459
Amortization of Goodwill & Intangibles	-	-	-	-	0.75
Operating Expenses	4,227	3,785	3,287	2,919	2,450
Operating Income	447.14	-569.01	-1,209	-1,790	-1,439
Interest Expense	-58.23	-14.74	-4.23	-19.11	-28.21
Interest & Investment Income	70.51	62.57	78.24	71.59	12.45
Earnings From Equity Investments	-	-10.28	-7.86	-3.68	-1.8
Other Non Operating Income (Expenses)	-42.55	7.35	-39.49	-195.13	8.31
EBT Excluding Unusual Items	416.85	-524.1	-1,182	-1,936	-1,448
Gain (Loss) on Sale of Investments	-	-8.9	-6.87	-25.04	9.39
Other Unusual Items	-	-	362.92	-	-
Pretax Income	416.85	-533	-825.84	-1,961	-1,439
Income Tax Expense	129.92	111.79	55.87	42.78	19.23
Earnings From Continuing Operations	286.93	-644.79	-881.71	-2,004	-1,458
Net Income	286.93	-644.79	-881.71	-2,004	-1,458
Net Income to Common	286.93	-644.79	-881.71	-2,004	-1,458
Shares Outstanding (Basic)	109	105	104	103	93
Shares Outstanding (Diluted)	113	105	104	103	93
Shares Change (YoY)	7.75%	0.86%	1.22%	11.15%	11.16%
EPS (Basic)	2.63	-6.12	-8.45	-19.43	-15.71
EPS (Diluted)	2.47	-6.12	-8.45	-19.43	-15.71
Free Cash Flow	1,128	-633.29	-1,719	-1,822	-1,562
Free Cash Flow Per Share	9.94	-6.01	-16.47	-17.67	-16.83
Gross Margin	87.49%	84.41%	84.55%	79.77%	85.98%
Operating Margin	8.37%	-14.93%	-49.15%	-126.40%	-122.31%
Profit Margin	5.37%	-16.92%	-35.86%	-141.52%	-123.93%
Free Cash Flow Margin	21.10%	-16.62%	-69.93%	-128.68%	-132.76%
EBITDA	576.79	-401.98	-1,125	-1,727	-1,393
EBITDA Margin	10.79%	-10.55%	-45.74%	-121.94%	-118.44%
D&A For EBITDA	129.66	167.03	83.94	63.05	45.49
EBIT	447.14	-569.01	-1,209	-1,790	-1,439
EBIT Margin	8.37%	-14.93%	-49.15%	-126.40%	-122.31%
Effective Tax Rate	31.17%	-	-	-	-
Revenue as Reported	5,343	3,810	2,459	1,416	1,176

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.